Anzeige
❌
Mehr »
Mittwoch, 07.10.2026 - Börsentäglich über 12.000 News
Gold Über 4.000 USD! 90 % der Lagerstätte getestet - es geht los!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MM

WKN: A42711 | ISIN: US60785L3069 | Ticker-Symbol:
NASDAQ
06.10.26 | 21:58
2,710 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
MODULAR MEDICAL INC Chart 1 Jahr
5-Tage-Chart
MODULAR MEDICAL INC 5-Tage-Chart

Aktueller Chart MODULAR MEDICAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
MODULAR MEDICAL INC-Investoren interessieren sich auch für diese Wertpapiere
Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer TransitionNEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with...
► Artikel lesen
Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of DirectorsNEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare...
► Artikel lesen
Biotech Stocks At 52-Week Highs - Cumberland Pharmaceuticals, Maravai LifeSciences, AngioDynamics, Acadia Healthcare, Teladoc HealthBENTONVILLE (dpa-AFX) - The following biotech stocks reached a 52-week high on July 15, 2026, driven by catalysts such as recent business developments or positive quarterly reports.Cumberland...
► Artikel lesen
Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical TrialTORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced...
► Artikel lesen
Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection...
► Artikel lesen
Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total PancreatectomyTORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused...
► Artikel lesen
Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile TestsHOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch...
► Artikel lesen
Cerenome, Inc.: Cerenome Expects $1.55 Million in CNSide Third Quarter Gross BillingsLead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30...
► Artikel lesen
Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics DivisionHOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha...
► Artikel lesen